动物实验,抑郁症 z-bo 2020-09-02 465

　　Japan’s Okayama Science University and other Japanese research teams confirmed that by using white mice for experiments, taking stomach medicine can improve depression symptoms, and announced the results of this study. In the future, we plan to conduct clinical studies in patients with depression to confirm the effects of stomach medicine on the human body.

　　Naoya Hashikawa (Molecular Biology), the backbone of the research team at the University’s Faculty of Science, said that the stomach medicine teprenone can improve symptoms of depression. When pressure stimulates and destroys cells, it induces heat shock protein (HSP) to prevent damage to cell structure. Methylprednisolone can promote the expression of heat shock protein (HSP). Studies have further confirmed that HSPs are closely related to the onset and symptoms of depression.

　　The research team placed mice in a laboratory cage (the laboratory cage contained a conscious mouse), and analyzed the brains of mice that were attacked, stressed, and exhibited depression. The hippocampus was found in the brain. Compared with normal white mice, the expression level of HSPs (involving memory and learning) was significantly lower. Therefore, after oral administration of teprenone, the mice's fear of other mice was reduced, and the depression symptoms were improved. Through research, the research team confirmed that increased HSP can promote nerve growth and regeneration, increased expression of antidepressant neurotrophic factor (BDNF), and revealed a mechanism for improving depression symptoms. 

     I chose In addition, the research team analyzed a database released by the US Food and Drug Administration to confirm the efficacy of teplerenone in humans. It is well known that the drug "interferon" used to treat hepatitis can cause depression. However, the research team proved through experiments that after taking teplerenone, the incidence of depression was reduced by about 40%. The research team said that existing antidepressants have obvious side effects, and new antidepressant mechanisms need to be developed. Mr. Hashikawa said: "The safety of pentenone has been confirmed. We will confirm its clinical efficacy and try to put it into practical use within a few years."